References
- Alderson, M. R., LaForce, F. M., Sobanjo-ter Meulen, A., Hwang, A., Preziosi, M. P., & Klugman, K. P. (2019). Eliminating meningococcal epidemics from the African meningitis belt: The case for advanced prevention and control using next-generation meningococcal conjugate vaccines. The Journal of Infectious Diseases, 220(Supplement_4), S274–S278. https://doi.org/10.1093/infdis/jiz297
- Ba, A., & Hoffmann, M. (Eds.). (2006). Contending perspectives on global governance: Coherence and contestation. Routledge.
- Berndtson, K., Daid, T., Tracy, C. S., Bhan, A., Cohen, E. R., Upshur, R. E., Singh, J. A., Daar, A. S., Lavery, J. V., & Singer, P. A. (2007). Grand challenges in global health: Ethical, social, and cultural issues based on key informant perspectives. PLoS Medicine, 4(9), e268. https://doi.org/10.1371/journal.pmed.0040268
- Bernstein, S., & Cashore, B. (2007). Can non-state global governance be legitimate? An analytical framework. Regulation & Governance, 1(4), 347–371. https://doi.org/10.1111/j.1748-5991.2007.00021.x
- The Bill and Melinda Gates Foundation. (2019). Foundation fact sheet. BMGF. Retrieved August 20, 2019, from https://www.gatesfoundation.org/Who-We-Are/General-Information/Foundation-Factsheet.
- Birn, A. E. (2005). A Gates's grandest challenge: Transcending technology as public health ideology. The Lancet, 366(9484), 514–519. https://doi.org/10.1016/S0140-6736(05)66479-3
- Birn, A. E. (2014). Philanthrocapitalism, past and present: The Rockefeller Foundation, the Gates Foundation, and the setting(s) of the international/global health agenda. Hypothesis, 12(1), e8. https://doi.org/10.5779/hypothesis.v12i1.229
- Birn, A. E., & Lexchin, J. (2011). Beyond patents: The gavi Alliance, amcs and improving immunization coverage through public sector vaccine production in the global south. Human Vaccines, 7(3), 291–292. https://doi.org/10.4161/hv.7.3.15217
- Bishai, D. M., Champion, C., Steele, M. E., & Thompson, L. (2011). Product development partnerships hit their stride: Lessons from developing a meningitis vaccine for Africa. Health Affairs, 30(6), 1058–1064. https://doi.org/10.1377/hlthaff.2011.0295
- Buse, K. (2004). Governing public-private infectious disease partnerships. Brown Journal of World Affairs, 10(2), 225–245.
- Buse, K., & Hawkes, S. (2016). Sitting on the FENSA: WHO engagement with industry. The Lancet, 388(10043), 446–447. doi: 10.1016/S0140-6736(16)31141-2
- Buse, K., & Walt, G. (2000a). Global public-private partnerships for health: Part I - A new development in health? Bulletin of the World Health Organization, 78(4), 549–561.
- Buse, K., & Walt, G. (2000b). Global public-private partnerships: Part II - What are the health issues for global governance? Bulletin of the World Health Organization, 78, 699–709.
- Chinedu, A., & Beswick, J. (2009). A comparison of the global Fund and the GAVI Alliance with emphasis on health system strengthening. Brandeis University.
- Clinton, C., & Sridhar, D. (2017). Governing global health: Who runs the world and why? Oxford University Press.
- Drezner, D. W. (2007). The new world order. Foreign Affairs, 86(2), 34–46.
- Duffy, M. J., & Freeman, C. P. (2011). Unnamed sources: A utilitarian exploration of their justification and guidelines for limited use. Journal of Mass Media Ethics, 26(4), 297–315. https://doi.org/10.1080/08900523.2011.606006
- Errante, A. (2000). But sometimes you're not part of the story: Oral histories and ways of remembering and telling. Educational Researcher, 29(2), 16–27. https://doi.org/10.3102/0013189X029002016
- Fejerskov, A. M. (2015). From unconventional to ordinary? The Bill and Melinda Gates Foundation and the homogenizing effects of international development cooperation. Journal of International Development, 27(7), 1098–1112. https://doi.org/10.1002/jid.3149
- Godlee, F. (1994). The World Health Organisation: WHO in crisis. British Medical Journal, 309(6966), 1424–1428. https://doi.org/10.1136/bmj.309.6966.1424
- Gostin, L. O., Sridhar, D., & Hougendobler, D. (2015). The normative authority of the World Health Organization. Public Health, 129(7), 854–863. https://doi.org/10.1016/j.puhe.2015.05.002
- Harman, S. (2016). The Bill and Melinda Gates Foundation and legitimacy in global health governance. Global Governance, 22(3), 349–368. https://doi.org/10.1163/19426720-02203004
- Hoffman, S. J., & Røttingen, J.-A. (2014). Split WHO in two: Strengthening political decision-making and securing independent scientific advice. Public Health, 128(2), 188–194. https://doi.org/10.1016/j.puhe.2013.08.021
- Hotez, P. (2011). A handful of ‘antipoverty’ vaccines exist for neglected diseases, but the world’s poorest billion people need more. Health Affairs, 30(6), 1080–1087. https://doi.org/10.1377/hlthaff.2011.0317
- Institute for Health Metrics and Evaluation. (2019). Financing global health 2018: Countries and programs in transition.
- International AIDS Vaccine Initiative. (2007, January 31). 30+ AIDS vaccine clinical trials in 24 countries: Research occurring on every continent. IAVI. http://www.iavi.org/Information-Centre/Press-Releases/Pages/AIDS-Vaccine-Trial-In-24-Countries.aspx
- Jadhav, S., Gautam, M., & Gairola, S. (2014). Role of vaccine manufacturers in developing countries towards global healthcare by providing quality vaccines at affordable prices. Clinical Microbiology and Infection, 20, 37–44. https://doi.org/10.1111/1469-0691.12568
- James, J. E. (2019). Can public financing of the private sector defeat antimicrobial resistance? Journal of Public Health, 41(2), 422–426. https://doi.org/10.1093/pubmed/fdy116
- Lee, K. (2008). The World Health Organization. Routledge.
- Mahoney, R. T. (2011). Product development partnerships: Case studies of a new mechanism for health technology innovation. Health Research Policy and Systems, 9(1), 33–33. https://doi.org/10.1186/1478-4505-9-33
- Mahoney, R. T., Ramachandra, S., & Xu, Z. Y. (2000) The introduction of new vaccines into developing countries II. Vaccine financing. Vaccine, 18(24), 2625–2635. https://doi.org/10.1016/S0264-410X(00)00073-6
- McArthur, J. W., & Rasmussen, K. (2019). An assessment of grant-based multilateral funding flows from 2014 to 2016. Global Policy, 10(2), 238–249. https://doi.org/10.1111/1758-5899.12653
- McCoy, D., Kembhavi, G., Patel, J., & Luintel, A. (2009). The Bill & Melinda Gates Foundation's grant-making programme for global health. The Lancet, 373(9675), 1645–1653. https://doi.org/10.1016/S0140-6736(09)60571-7
- McGoey, L. (2015). No such thing as a free gift: The Gates Foundation and the price of philanthropy. Verso.
- McNeill, D., & Sandberg, K. I. (2014). Trust in global health governance: The GAVI experience. Global Governance: A Review of Multilateralism and International Organizations, 20(2), 325–343. doi: 10.1163/19426720-02002009
- Moran, M. (2014). Private foundations and development partnerships: American philanthropy and global development agendas. Routledge.
- Moran, M., Guzman, J., Ropars, A. L., & Illmer, A. (2010). The role of product development partnerships in research and development for neglected diseases. International Health, 2(2), 114–122. https://doi.org/10.1016/j.inhe2010.04.002 doi: 10.1016/j.inhe.2010.04.002
- Moran, M., & Stevenson, M. (2013). Illumination and innovation: What philanthropic foundations bring to global health governance. Global Society, 27(2), 117–137. doi: 10.1080/13600826.2012.762343
- Muraskin, W. (1998). The politics of international health: The children's vaccine initiative and the struggle to develop vaccines for the third world. SUNY Press.
- Muraskin, W. (2005). Crusade to immunize world’s children, The origins of Bill and Melinda Gate’s children’s vaccine programme and the birth of global alliance for vaccines and immunization. USC Marshall Global biobusiness books Initiative.
- Novak, A. (2014). Anonymity, confidentiality, privacy, and identity: The ties that bind and break in communication research. Review of Communication, 14(1), 36–48. https://doi.org/10.1080/15358593.2014.942351
- Pécoul, B. (2004). New drugs for neglected diseases: From pipeline to patients. PLoS Medicine, 1(1), e6. https://doi.org/10.1371/journal.pmed.0010006
- Ramiah, I., & Reich, M. R. (2006). Building effective public–private partnerships: Experiences and lessons from the African Comprehensive HIV/AIDS Partnerships (ACHAP). Social Science & Medicine, 63(2), 397–408. https://doi.org/10.1016/j.socscimed.2006.01.007
- Rey-Garcia, M., Martin-Cavanna, J., & Alvarez-Gonzalez, L. I. (2012). Assessing and advancing foundation transparency: Corporate foundations as a case study. The Foundation Review, 4(3), 77–89. https://doi.org/10.4087/FOUNDATIONREVIEW-D-12-00003.1
- Risse, T. (2007). Transnational actors and world politics. In W. C. Zimmerli, K. Richter, & M. Holzinger (Eds.), Corporate ethics and corporate governance (pp. 251–286). Springer.
- Roemer-Mahler, A. (2014). The rise of companies from emerging markets in global health governance: Opportunities and challenges. Review of International Studies, 40(5), 897–918. https://doi.org/10.1017/S0260210514000345
- Rosenau, J. N. (2007). Governing the ungovernable: The challenge of a global disaggregation of authority. Regulation & Governance, 1(1), 88–97. https://doi.org/10.1111/j.1748-5991.2007.00001.x
- Rosenau, J. N., & Czempiel, E. O. (Eds.). (1992). Governance without government. Cambridge University Press.
- Ruckert, A., & Labonté, R. (2014). Public–private partnerships (ppps) in global health: The good, the bad and the ugly. Third World Quarterly, 35(9), 1598–1614. https://doi.org/10.1080/01436597.2014.970870
- Ruggie, J. G. (1983). Continuity and transformation in the world polity: Toward a neorealist synthesis. World Politics, 35(2), 261–285. https://doi.org/10.2307/2010273
- Ruggie, J. G. (2004). Reconstituting the global public domain—issues, actors and practices. European Journal of International Relations, 10(4), 499–531. https://doi.org/10.1177/1354066104047847
- Rushton, S., & Williams, O. D. (2012). Frames, paradigms and power: Global health policy-making under neoliberalism. Global Society, 26(2), 147–167. https://doi.org/10.1080/13600826.2012.656266
- Scholte, J. A. (2005). Globalization: A critical introduction. Palgrave MacMillan.
- Schwab, K. (2008). Global corporate citizenship: Working with governments and civil society. Foreign Affairs, 87(1), 107–118.
- Shepard, A. C. (1994). Anonymous sources. American Journalism Review, 16(10), 18–26.
- Shepard, J. M. (2019). Anonymous sources and source confidentiality. The International Encyclopedia of Journalism Studies. https://doi.org/10.1002/9781118841570.iejs0258
- Silberschmidt, G., Matheson, D., & Kickbusch, I. (2008). Creating a committee C of the world health assembly. The Lancet, 371(9623), 1483–1486. https://doi.org/10.1016/S0140-6736(08)60634-0
- Sridhar, D., & Gostin, L. O. (2011). Reforming the World Health Organization. Journal of the American Medical Association, 305(15), 1585–1586. https://doi.org/10.1001/jama.2011.418
- Sternadori, M. M., & Thorson, E. (2009). Anonymous sources harm credibility of all stories. Newspaper Research Journal, 30(4), 54–66. https://doi.org/10.1177/073953290903000405
- Stevens, A. J., Jensen, J. J., Wyller, K., Kilgore, P. C., Chatterjee, S., & Rohrbaugh, M. L. (2011). The role of public-sector research in the discovery of drugs and vaccines. New England Journal of Medicine, 364(6), 535–541. https://doi.org/10.1056/NEJMsa1008268
- Stevenson, M. A. (2018). Geneva-Seattle collaboration in support of developing country vaccine manufacturing. Global Public Health, 13(4), 426–441. doi: 10.1080/17441692.2016.1245349
- Stevenson, M. (2017). PATH: Pioneering innovation for global health at the public–private interface. Third World Quarterly, 38(8), 1873–1893. https://doi.org/10.1080/01436597.2016.1233491
- Storeng, K. (2014). The GAVI Alliance and the ‘Gates approach’ to health system strengthening. Global Public Health, 9(8), 865–879. https://doi.org/10.1080/17441692.2014.940362
- Strange, S. (1996). The retreat of the state: The diffusion of power in the world economy. Cambridge University Press.
- Trouiller, P., Olliaro, P., Torreele, E., Orbinski, J., Laing, R., & Ford, N. (2002). Drug development for neglected diseases: A deficient market and a public-health policy failure. The Lancet, 359(9324), 2188–2194. https://doi.org/10.1016/S0140-6736(02)09096-7
- Wallace, L., & Kapirir, L. (2017). How are new vaccines prioritized in low-income countries? A case study of human papilloma virus vaccine and pneumococcal conjugate vaccine in Uganda. International Journal of Health Policy and Management, 6(12), 707–720. https://doi.org/10.15171/ijhpm.2017.37
- Wheeler, C., & Berkley, S. (2001). Initial lessons from public-private partnerships in drug and vaccine development. Bulletin of the World Health Organization, 79(8), 728–734.
- Widdus, R., & White, K. (2004). Combating diseases associated with poverty: Financing strategies for product development and the potential role of public-private partnerships. Institute for Public-Private Partnerships for Health.
- Wittet, S. (2000). Introducing GAVI and the global fund for children’s vaccines. Vaccine, 19(19), 385–386. https://doi.org/10.1016/S0264-410X(00)00196-1
- World Health Organization. (2016). Framework of engagement with non-State actors (FENSA). Sixty-Ninth World Health Assembly.
- World Health Organization. (2019). Voluntary contributions specified. WHO. Retrieved August 20, 2019, from http://open.who.int/2018-19/contributors/overview/vcs
- Yamey, G. (2002). WHO in 2002: Why does the world still need WHO? British Medical Journal, 325(7375), 1294–1298. https://doi.org/10.1136/bmj.325.7375.1294